Skip to content
10-Q

Quarterly Report

CYTOSORBENTS CORPORATION CTSO

0001410578-25-001612

← back to feed
Filed
Aug 7, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 1, 2025 62.76M sh
Shares Diluted Q2 2025 · Jun 30, 2025 67.17M sh
Shares Diluted Q2 2025 · Jun 30, 2025 66.26M sh
Shares Diluted Q2 2025 · Jun 30, 2024 54.31M sh
Shares Diluted Q2 2025 · Jun 30, 2024 54.28M sh
Capex Q2 2025 · Jun 30, 2025 $39K
Capex Q2 2025 · Jun 30, 2024 $63K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$4.98M
Operating Cash Flow restated Q2 2025 · Jun 30, 2024 −$9.62M
Long Term Debt Q2 2025 · Jun 30, 2025 $14.38M
Long Term Debt Q2 2025 · Dec 31, 2024 $14M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $10.2M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $3.28M
Stockholders Equity Q2 2025 · Jun 30, 2025 $11.59M
Stockholders Equity Q2 2025 · Mar 31, 2025 $14.54M
Stockholders Equity Q2 2025 · Dec 31, 2024 $11.11M
Stockholders Equity restated Q2 2025 · Jun 30, 2024 $17.43M
Stockholders Equity restated Q2 2025 · Mar 31, 2024 $19.63M
Stockholders Equity restated Q2 2025 · Dec 31, 2023 $23.48M
Current Liabilities Q2 2025 · Jun 30, 2025 $9.84M
Current Liabilities Q2 2025 · Dec 31, 2024 $9.83M
Total Liabilities Q2 2025 · Jun 30, 2025 $36.4M
Total Liabilities Q2 2025 · Dec 31, 2024 $36.27M
Current Assets Q2 2025 · Jun 30, 2025 $22.99M
Current Assets Q2 2025 · Dec 31, 2024 $21.6M
Total Assets Q2 2025 · Jun 30, 2025 $47.99M
Total Assets Q2 2025 · Dec 31, 2024 $47.37M
Eps Diluted Q2 2025 · Jun 30, 2025 $0.03
Eps Diluted Q2 2025 · Jun 30, 2025 $0.01
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.08
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.19
Eps Basic Q2 2025 · Jun 30, 2025 $0.03
Eps Basic Q2 2025 · Jun 30, 2025 $0.01
Eps Basic Q2 2025 · Jun 30, 2024 −$0.08
Eps Basic Q2 2025 · Jun 30, 2024 −$0.19
Sga Expense Q2 2025 · Jun 30, 2025 $9.17M
Sga Expense Q2 2025 · Jun 30, 2025 $17.6M
Sga Expense restated Q2 2025 · Jun 30, 2024 $8.55M
Sga Expense restated Q2 2025 · Jun 30, 2024 $17.84M
Net Income Q2 2025 · Jun 30, 2025 $1.95M
Net Income Q2 2025 · Jun 30, 2025 $469K
Net Income restated Q2 2025 · Jun 30, 2024 −$4.29M
Net Income restated Q2 2025 · Jun 30, 2024 −$10.38M
Operating Income Q2 2025 · Jun 30, 2025 −$3.62M
Operating Income Q2 2025 · Jun 30, 2025 −$7.5M
Operating Income restated Q2 2025 · Jun 30, 2024 −$3.57M
Operating Income restated Q2 2025 · Jun 30, 2024 −$8.23M
Gross Profit Q2 2025 · Jun 30, 2025 $6.81M
Gross Profit Q2 2025 · Jun 30, 2025 $13.02M
Gross Profit restated Q2 2025 · Jun 30, 2024 $6.5M
Gross Profit restated Q2 2025 · Jun 30, 2024 $13.38M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $2.8M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $5.32M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $2.34M
Cost Of Revenue restated Q2 2025 · Jun 30, 2024 $4.46M